

# Supporting Information

Sen Santara et al. 10.1073/pnas.1304145110

## SI Methods

**Protein Expression and Purification.** For expression of recombinant full-length heme containing adenylate cyclase from *Leishmania major* (HemAC-Lm) and the catalytic domain ( $\Delta$ 360HemAC-Lm), the corresponding plasmids were transformed separately into competent *Escherichia coli* BL21(DE3). Overnight-grown culture was inoculated in 500 mL of modified terrific broth, incubated at 37 °C for 5 h, and induced with 0.5 mM isopropyl  $\beta$ -D-1-thiogalactopyranoside followed by addition of 0.4 mM  $\delta$ -aminolevulinic acid. *E. coli* cells were grown at 22 °C and 180 rpm for 20 h, pelleted, and resuspended in 50 mM Tris-HCl buffer, pH 7.5, containing 0.5 mM EDTA, 10% glycerol, 150 mM NaCl, protease inhibitor mixture (Roche), 0.5 mM PMSF, and 1.0 mg/mL lysozyme. The resuspended solution was kept for 1 h on ice at 4 °C, and then the cells were broken by sonication. The lysate was centrifuged at  $14,000 \times g$  for 1 h. The supernatant or the crude extract was loaded onto a  $\text{Ni}^{2+}$ -nitrilotriacetate column. After loading the crude extract, the column was washed with 10 column volumes of washing buffer [50 mM Tris-HCl buffer (pH 7.5), 150 mM NaCl, 10% glycerol, and 1 mM PMSF]. The enzyme was eluted with the washing buffer supplemented with 150 mM imidazole and then dialyzed three times against 50 mM Tris-HCl buffer (pH 7.5), 150 mM NaCl, and 10% glycerol. Then the dialyzed fraction was concentrated and loaded into Superdex 200 Columns of ÄKTApriime plus system (GE Healthcare). Purification of  $\Delta$ 360HemAC-Lm catalytic domain was carried out in the same way as above except  $\delta$ -aminolevulinic acid was excluded during induction and no gel filtration was performed after elution from the  $\text{Ni}^{2+}$ -nitrilotriacetate column. Molecular weight and purity of the proteins were confirmed by 12% SDS PAGE.

**Enzyme Assay.** Enzymatic reactions were initiated by addition of 100–150  $\mu\text{g}$  of enzyme to the reaction mixture (final volume of 175  $\mu\text{L}$ ) containing 20 mM Tris-HCl buffer (pH 7.5), 1 mM 1-methyl-3-isobutyl-xanthine, 5 mM ATP, 1 mM  $\text{MgCl}_2$ , 10 mM  $\text{MnCl}_2$ , and 10 mM NaCl. Assay incubations were routinely conducted for 15 min at 37 °C, terminated by placing into boiling water bath for 1 min and filtered by Amicon ultra 3.0 kDa (millipore). Sixty microliters of the filtrate was injected in an HPLC chromatographic system (Waters 1525 binary HPLC pump), connected to a Symmetry 300 5- $\mu\text{m}$  C-18 (250  $\times$  4.6 mm) column with a C-18 guard column (Waters). The HPLC run was conducted at isocratic mode with 50 mM phosphate buffer (pH 4.3) containing 0.2% triethylamine-methanol (90:10) at a flow rate of 1 mL/min. Peaks were monitored with a Waters 2489 UV/Visible Detector at 260 nm. The amount of cAMP produced during the enzymatic reaction was determined by external standardization, being the linearity between peak areas and the masses of cAMP injected in the range 0.1–500 nano moles ( $r = 0.999$ ).

**Preparation of Deoxy Protein.** Deoxy ferrous form of HemAC-Lm was prepared by incubating the protein with the strong reducing agent sodium dithionite inside the anaerobic chamber (atmosbag, Aldrich) followed by immediate removal of the excess dithionite by gel filtration on a Sephadex-G25 column (2 mL) equilibrated with  $\text{N}_2$ -equilibrated anaerobic buffer containing 50 mM Tris-HCl buffer (pH 7.4), 50 mM NaCl, and 10% (vol/vol) glycerol. The ferrous deoxygenated sample was collected into an anaerobic rubber-sealed cuvette. Then the UV-visible spectrum was taken for verification of full conversion from ferrous oxygenated form to ferrous deoxygenated form and for measuring protein concentration.

For preparation of anaerobic Sephadex-G25 column within the anaerobic chamber, the column was washed twice with 100  $\mu\text{L}$  sodium dithionite solutions (1 mg/mL) followed by extensive washing with  $\text{N}_2$ -equilibrated anaerobic buffer before sample loading.

**Subcellular Fractionation and Western Blotting.** Subcellular fractionation was performed to separate mitochondria, nuclei, cytosol, and microsomal fractions by the mitochondria isolation kit (Qiagen). The purity of each fraction was checked by Western blot analysis with organelle-specific marker antibodies. The primary antibodies used were as follows: mouse anti-(*L. major*)-HemAC antibody (1:100), rabbit anti-(*L. major*) ascorbate peroxidase (1:50), rabbit anti-(*Leishmania donovani*)-adenosine kinase (1:50), and rabbit anti-(*Trypanosoma brucei*) Bip antibody (1:1,000). The HRP-conjugated secondary antibodies used were anti-rabbit (1:10,000), and anti-mouse (1:6,000).

**Generation of Stable Knockout Strain for HemAC-Lm Alleles.** To generate the constructs pXG-NEO HemAC-Lm and pXG-HYG HemAC-Lm, 1.007 kb from the 5' region and 1 kb from the 3' region of the HemAC-Lm gene were inserted into the modified pXG-NEO and pXG-HYG vectors (1), respectively. Primers 7/8 (Table S1) were used for amplifying the 5' flank, and primers 9/10 (Table S1) were used for amplifying the 3' flank of the gene. The HindIII/SalI-digested 5' flanking region and the SmaI/BamHI-digested 3' flanking region were cloned on either side of ORFs encoding neomycin and hygromycin resistance genes of pXG-NEO and pXG-HYG vectors, respectively. Both constructs were then digested with HindIII and BamHI to get linear fragments of gene deletion constructs HemAC-Lm::NEO and HemAC-Lm::HYG. HemAC-Lm::NEO construct was transfected in log-phase promastigotes to generate heterozygous knockouts (HKOs). HKO strain with HemAC-Lm::NEO construct was maintained at 200  $\mu\text{g}/\text{mL}$  neomycin. To generate double-knockout parasites, HemAC-Lm::HYG construct was transfected into the HKO parasites. HKO was confirmed by PCR using primers 11/12 as external to the gene to detect proper insertion of cassettes into the transformant genomic DNA. The double-knockout strain was unable to grow in growth medium containing 60  $\mu\text{g}/\text{mL}$  neomycin and 100  $\mu\text{g}/\text{mL}$  hygromycin drug.

**Inducible Gene Expression Strain (LmT7.TR) Construction.** A 2.7-kbp fragment encoding T7 RNA polymerase containing N-terminal nuclear localization signal (NLS) was amplified by PCR using primers 13/14 from pLew13 plasmid (Addgene plasmid 24007). The resulting PCR product was digested with BglII and NotI and cloned into *Leishmania* expression vector pLEXY-hyg2 (Jena Bioscience) with the same enzymes to generate pLEXY-hyg2-T7polNLS construct. *L. major* promastigotes were transfected with SmaI linearized pLEXY-hyg2-T7polNLS plasmid. Linearized pLEXY-hyg2-T7polNL plasmid contains T7 RNA polymerase and its 5' ssu and 3' ssu regions. The 5' ssu and the 3' ssu regions are responsible for homologous recombination into 18S rRNA locus of host chromosome. Hygromycin-resistant transformants were maintained at 200  $\mu\text{g}/\text{mL}$  hygromycin. Finally, hygromycin-resistant transformants were further transfected with AatII-digested pLew114hyg5' vector for the generating LmT7.TR cells. The pLew114hyg5' vector contains tetracycline repressor sequence, and it has the capability for homologous recombination into hygromycin locus of hygromycin cassette. LmT7.TR clones were maintained in 200  $\mu\text{g}/\text{mL}$  neomycin. The incorporation of T7RNA polymerase gene and tetracycline repressor

sequence in LmT7.TR clones were confirmed by PCR using primers 15/16 and primers 17/18, respectively.

**Construction of Inducible Knockdown Cell Line for HemAC-Lm.** An antisense construct of HemAC-Lm (pLewHemAC-Lm) was generated by cloning a segment from the 5' terminus using primers 19/20 and cloned in reverse orientation into the HindIII- and BamHI-digested pLEW82v4 vector which contains T7 promoter and a tetracycline operator sequence. The pLewHemAC-Lm was transfected in the LmT7.TR promastigotes by electroporation to generate tetracycline inducible knockdown for HemAC-Lm gene (IKO) cell line. The IKO cell line was selected by using 25 µg/mL phleomycin and 200 µg/mL neomycin.

**Detection of Intracellular cAMP in *L. major* Cells.** Intracellular concentration of cAMP in control (CT), IKO, HKO, and overexpressing (OE) cells, incubated either at normoxic or hypoxic condition, were determined by cAMP complete ELISA kit (Enzo Life Sciences). Briefly,  $2 \times 10^7$  cells were centrifuged and washed twice with Tris buffer saline and homogenized in 400 µL of 0.1 M HCl. Homogenized samples were centrifuged at 10,000 rpm to collect the supernatant. The 200-µL test samples were mixed with 10 µL acetylating reagent mix and vortexed immediately to acetylate cAMP. Then 50 µL of neutralizing reagent was added to a goat anti-rabbit IgG-coated 96-well plate followed by the sequential addition of 100 µL of the acetylated test samples or standards, 50 µL of cAMP conjugate, and 50 µL of cAMP Antibody. The plate was then incubated for 2 h with mild shaking. The plate was then washed five times with wash buffer and was developed by incubating with p-nitrophenyl phosphate solution for 1 h followed by addition of 50 µL stop solution to each well. Reading was taken at 405 nm. All incubations were performed at room temperature.

**PKA Activity Assay.** PKA activity was assayed in *L. major* lysates as described by Malki-Feldman et al. (2) by phosphorylation of the specific fluorescent PKA substrate kemptide using the PepTag Non-Radio-active PKA Assay (Promega) kit. Briefly, log-phase cells were harvested and washed twice at  $1,200 \times g$  (4 °C) for 5 min with washing buffer [20 mM Tris-HCl (pH 7.5), 100 mM NaCl]. The cell pellets were suspended in wash buffer supplemented with 1:25 diluted protease inhibitors (complete-protease inhibitor tablets; Roche). Using a 26-gauge needle and freeze-thawing three times,  $5.0 \times 10^6$  cells per µL were disrupted. Extracts were precleared by centrifuging at  $17,000 \times g$  for 15 min at 4 °C. The aliquots were assayed in 25 µL reaction volume for 30 min at 30 °C. Phosphorylated and nonphosphorylated PepTag peptides were separated by electrophoresis (100 V, 20–30 min) in 0.8% agarose gels in 50 mM Tris-HCl buffer, pH 8. UV-illuminated gels were photographed, and the digital images were analyzed by densitometry using ImageJ software. Kemptide phosphorylation by control cell lysate in the absence of inhibitors or activators was arbitrarily set, and the PKA activity of other cell types was calculated relative to this value and presented as the mean  $\pm$  SD. Experiments were repeated at least twice.

**Metacyclic Purification Assay.** To study the metacyclogenesis in promastigotes, log-phase promastigote cultures of each type of cells were washed with PBS, resuspended to  $10^8$ /mL cell density, and incubated with 50 µg/mL of peanut agglutinin (PNA). After

30 min of incubation at room temperature, the suspension was centrifuged at  $40 \times g$  for 5 min. The nonagglutinated promastigotes (PNA<sup>-</sup>) were collected from supernatant by centrifugation for 5 min at  $1,200 \times g$  and washed twice with PBS. Cells were resuspended in PBS and analyzed for light scatter by flow cytometry. Dot plots of forward-angle light scatter vs. side-angle light scatter of the whole sample were taken.

**Cell Death Assessment by PI and Annexin V Staining.** Phosphatidylserine exposure was assessed by ApoAlert annexin V apoptosis kit (Clontech). After the incubation in the hypoxic condition, cells were harvested at 4 °C by centrifugation for 5 min at  $1,200 \times g$  and washed twice with cold  $1 \times$  binding buffer. The cells were resuspended in 200 µL of  $1 \times$  binding buffer, following the addition of 5 µL of FITC-conjugated annexin V (20 µg/mL) and 10 µL of propidium iodide (50 µg/mL). Cells were incubated at room temperature for 5–15 min in the dark and analyzed by flow cytometry.

For microscopy, FITC-conjugated annexin V and PI-labeled equivalent cells were adhered to poly-L-lysine-coated slide and visualized with an Olympus IX81 microscope. For each sample, ~20 fields were observed.

**Cell Cycle Analysis.** Flow cytometric analysis of cell cycle was performed as follows: about  $1 \times 10^7$  cells were centrifuged and transferred into fresh M199 medium containing 200 µg/mL hydroxyurea and incubated at 25 °C for 12 h for synchronization. The cells were washed and transferred into fresh M199 media containing 10% FCS without hydroxyurea. Aliquotes were taken at 2 h interval and harvested by centrifugation. Cells were then washed twice with PBS and suspended in 200 µL PBS. For fixation, 2 mL of ice cold 70% ethanol was added dropwise to cell suspension with gentle vortexing and left overnight at 4 °C. Before analysis, the cells were treated with 20 mg/mL RNase for 1 h at 37 °C. Subsequently, DNA was stained using propidium iodide (200 µg/mL). The samples were analyzed on a FACS Calibur (Becton Dickinson), and the proportions of G1, S, and G2-M populations were determined using ModFit software. Around 20,000 events were collected for each sample.


**Quantitative Real-Time PCR.** Oxidative stress response of CT, HKO, IKO, and OE was analyzed by relative quantification mRNA levels of five important antioxidant genes of *Leishmania*: non-selenium glutathione peroxidase (LmjF.26.0810), iron superoxide dismutaseA (LmjF08.0290), peroxidoxin trypanredoxin peroxidase (LmjF23.0040), superoxide dismutase (LmjF30.2770), and trypanredoxin peroxidase (LmjF.15.1120). Total RNA was extracted from CT, HKO, IKO, and OE *Leishmania* cells using an RNAqueous-4PCR kit (Ambion) according to the manufacturer's protocol. RNA quantification was measured by comparing absorbance at 260/280-nm wavelengths. Then the cDNA synthesis from 2 µg of RNA of each cell type was done by using a High Capacity cDNA reverse transcription kit (Applied Biosystems). Quantitative real-time PCR was then done with the cDNA on StepOne instrument (Applied Biosystems) using SYBR Green dye (Applied Biosystems) as the reporter dye according to the manufacturer's protocol. The mRNA quantification was done by comparative C<sub>T</sub> method using 18 S rRNA as the reference gene.

1. Pal S, Dolai S, Yadav RK, Adak S (2010) Ascorbate peroxidase from *Leishmania major* controls the virulence of infective stage of promastigotes by regulating oxidative stress. *PLoS ONE* 5(6):e11271.

2. Malki-Feldman L, Jaffe CL (2009) *Leishmania major*: Effect of protein kinase A and phosphodiesterase activity on infectivity and proliferation of promastigotes. *Exp Parasitol* 123(1):39–44.

HemAC-Lm	mlcwntrrdskefgheavemds lqancgapnega fhdtlvsaayqlrarqrdrtnvs iskaemeglvvltrelenfkqmmkr	81
HemAC-Li	mlcwntrrdskefghevvetds lqancgapnega fhdtlvsaahqlrarqrdrtnvs iskaemeglvvltrelenlkqmmkr	142
AsHb1		ank 3
BtHbA		vlsaa 5
MgHbIII		pitdhgqpptlseg 14
BcMb		gldga 5
	* * * *	
HemAC-Lm	seftVEGTW rivedggmve--RFGQQLY AELLTRNPrLRVHFhgvd-----IEEQSKSLLRMVGTAVHfyqkpx	148
HemAC-Li	seftVEGTW riledegmve--RFGQQLY DELLTRNPrLRVYFhgvd-----IKEQSKSLLRMVGTAVHfyqkpx	209
AsHb1	tre lCMKSL eHakvdt s nearQDGLDLYKHM FENYPpLRKYFksreeyt aedvqndp fFAKQGGKILLACHVLCAt yddre	84
BtHbA	dkgnVKA AWgkvvgghaa---EYGA EALERMF LSPtTKTYFphfdlshgsaq---VKGHGAKVAAALTKAVEHldd lp	77
MgHbIII	dkkaIRE SWeswpqi yknfe-QNSLAVLLEFLKKFPkAQDSFpkfs akks hlegdpavK LQAEVVIINAVNHTIGlmdkea	93
BcMb	qktaLKE SWkvlgadgptmm-KNGSLLFGLL FKTYPdTKKHfkhfddat faamdttgvGKAHGVA VFSGLGSMTCs idddd	85
	** * *	
HemAC-Lm	ltvdmftKAGARHRGyg vnae--VFVEMR NAFMRVfsefvgt dv feavEEWRKFWKYVLDLLvhg ses aeger ygkmyee	227
HemAC-Li	ltvdmftKAGARHRGyg vnae--VFVEMSN AFMRVf skfvgt dv fqaEEWRKFWKYVLDLLvhg ses peger ygkvyee	288
AsHb1	tfnaytrELDRHARDhvmppeVWTD FWKLFEE YLgkkt l ldept--KQAWHE IGRFAKE I	145
BtHbA	gals---ELSDLHAHk lrvdpv-NFKLLSHSL LVTLash lpsdftpavHASLDKFLANVSTVL	136
MgHbIII	amkky lkDLSTKHSTefq vnp--MFKELSA VFVSTMgg-----KAAYEK LFS IIATLL	142
BcMb	cvbglakKLSRNHLArgvsa a--DFKLEAVFKZFLdeatqrkatdaqKDADGALLTMLIKAH	146
HemAC-Lm	knkltiqadfk limerq nkc dlrgqfvsvmyska iemheelskfealkdlrasarvlqayidi inn ihdklldeymrelg	308
HemAC-Li	knkkkigsdfk limerq nrc dlrrqfvsvmyskamemheelskfealkdlrasarvlqsyidvinn ihdklldeymrelg	369
	* **	
HemAC-Lm	grhtaynvtvenlqaftepf lftcrhf feeewniaaesrflwlfeymidgis agmvsdins ivn lrapsnsvtfgLIFTDI	389
HemAC-Li	grhtaynvtvenlhaftepf lftcrhf ledewniaavesrllwlfeymidgis agmvsdins ivn lrapsusvsfgLIFTDI	450
CsGC		gidpftkmgdrrpitILTSDL 22
SpcAC		mgs shhhhhh ssglvprgshmrpepr litILFSDI 35
CfAC		memkadinakqedmmfhkiyiqkhdnvsILFADI 34
	**** * * * *	
HemAC-Lm	EASTrlwskdsksm-SLAVKSHHAMIRRLIadygAYEVKTVGDSFI IAtk-----DVLVAVKLSLAIQLEIMrmapl	460
HemAC-Li	EASTrlwskdsqsm-SLAVKSHHAMIRRLIadygAYEVKTVGDSFI IAtk-----DVLVAVKLSLSIQLEIMrmapl	521
CsGC	RGFTstseg lnpeevVKVLNIYFGKMADV It hhgGT IDEFMGDG ILVLFgaptsqgd--DALRAVACGVEMQLALRevncq	101
SpcAC	VGFTrmsnalqsgqvAE LLNEYLGEMT RAVfengqT VDKFVGDAIMALygapeemspseQVRRRAIATARQMLVALEk lnqg	116
CfAC	EGFTslasqctaqelVMTLNELFARFDKLAaenhCLRILKILGDCYYCVsglpearad--HAHCCVEMGMDMIEAISlvrem	113
	*** ** *	
HemAC-Lm	apgfamvdsteqhgdpqawddrtLRVRIGVehCTDATA-Tydtihrr-YDYYGASVNR CARIEAAAcgQOILLCRESF EYL	539
HemAC-Li	apgfamvdsseg hgdppqawddrtLRVRIGVehCTDATA-Tydtihrr-YDYYGASVNR CARIESAACgQOILLSRESFEHL	600
CsGC	wtg lglqp-----LEMGIGI-NTGEVVVgNigsekr tkYGVVGAQVNLT YRIES YttgQOIF ISSTTLEAa	166
SpcAC	wqerglvgrnevpp-----VRFRCGI-HQGMVAVgLfgsqers dFTAIGP SVN IAARLQEAT apNSIMVSA MVAQYV	187
CfAC	tgvn-----VNMRVGI-HSGRVHCgVlg lrkwq-FDVWSNDVTL ANHMEAGGk aGRIHTKATLSYL	173
	*	
HemAC-Lm	ksmpafhndpcphflrhveiatpppkvdsrgldhfvvVSDVGLa---SFKGiaePVHLLSLVprclagrqftekftkvse	616
HemAC-Li	ksipefhndepcphflrsvveiatpppkedsrgldhfvvVSDVGLa---SFKGiaePVHLLVSLVprclagrqftekftkvae	677
CsGC	g-----drvhvNGNRTv-----QPKGvkdPVVIWDV	192
SpcAC	p-----deeiLKREFL-----ELK GidePVMTCVI	212
CfAC	n-----gdyeVEPGCggernaYLKEh--SIETFLI	201

Fig. S1. Sequence analysis of HemAC-Lm. Amino acid sequence of HemAC-Lm was aligned with heme containing adenylate cyclase from *Leishmania infantum* (HemAC-Li), *Ascaris suum* Hemoglobin Domain I (AsHb1), *Bos taurus* deoxyhemoglobin A (BtHbA), *Myxine glutinosa* hemoglobin III (MgHbIII), *Busycotypus canaliculatus* myoglobin (BcMb), *Cyanobacterium synechocystis* sp. PCC guanylyl cyclase (CsGC), *Spirulina platensis* soluble adenylate cyclase Cyac (SpcAC), and *Canis lupus familiaris* adenylate cyclase (CfAC). Lowercase amino acids are unaligned. Dashes indicate variations in sequence length among aligned proteins. Uppercase amino acids are aligned and used to generate a position-specific scoring matrix. Asterisk indicates heme-binding site and nucleotidyl-binding site residue.



**Fig. S2.** DNA content distribution of CT, OE, HKO, and IKO cells after removing the hydroxyurea block. The log-phase cells ( $<10^7$ /mL) were synchronized at the G1-S border with 200  $\mu$ g hydroxyurea for 12 h. DNA content was measured after staining with propidium iodide, and the cell cycle phases were analyzed by flow cytometry at different time intervals up to 12 h. The fraction of cells in G1/G0 and G2/M phases of the cell cycle (red) and the fraction of cells in S phase of the cell cycle (blue hatched areas) were calculated by Mod-fit software.

